Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rh-BNP plus diuretics vs diuretics alone in type 1 cardiorenal syndrome (VExUS-guided)
ChiCTR2500105942Phase 4Not yet recruiting
- Sponsor
- Department of Critical Care Medicine, Tianjin First Center Hospital
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of nesiritide in Cardiorenal syndrome type 1 (CRS-1) (2 arms), sponsored by Department of Critical Care Medicine, Tianjin First Center Hospital. Primary endpoints: Left ventricular ejection fraction at day 7, VExUS score at day 7 and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
Cardiorenal syndrome type 1 (CRS-1)
Beyond the preview
Go deeper on ChiCTR2500105942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105942.